The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
D-type cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell proliferation. Inhibitors of CDK4 and CDK6 are currently being tested in clinical trials for patients with several cancer types, with promising results. Here, using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kinase phosphorylates and inhibits the catalytic activity of two key enzymes in the glycolytic pathway, 6-phosphofructokinase and pyruvate kinase M2. This re-directs the glycolytic intermediates into the pentose phosphate (PPP) and serine pathways. Inhibition of cyclin D3-CDK6 in tumour cells reduces flow through the PPP and serine pathways, thereby depleting the antioxidants NADPH and glutathione. This, in turn, increases the levels of reactive oxygen species and causes apoptosis of tumour cells. The pro-survival function of cyclin D-associated kinase operates in tumours expressing high levels of cyclin D3-CDK6 complexes. We propose that measuring the levels of cyclin D3-CDK6 in human cancers might help to identify tumour subsets that undergo cell death and tumour regression upon inhibition of CDK4 and CDK6. Cyclin D3-CDK6, through its ability to link cell cycle and cell metabolism, represents a particularly powerful oncoprotein that affects cancer cells at several levels, and this property can be exploited for anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The cyclin D3/CDK6 kinase complex can phosphorylate 6-phosphofructokinase and pyruvate kinase M2 (Wang et al., 2017).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“This has the effect of pushing glycolytic intermediates into the pentose phosphate and serine pathways, and inhibition of CDK6 (through treatment with palbociclib, ribociclib, or knockdown of CDK6) depletes the antioxidants NADPH and glutathione, increasing ROS and apoptosis.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
In the citing paper
“These cells express very low levels of cyclin D1, cyclin D2, and CDK4, and the proliferative decision is dependent upon cyclin D3 and CDK6 (Wang et al., 2017; Wolowiec et al., 1996).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Wang et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Elias, J. E., & Gygi, S. P. (2007) · Nature Methods · doi:10.1038/nmeth1019 · Cited by 3,925
Self-citationThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
A tissue-specific atlas of mouse protein phosphorylation and expression
Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villén, J., Haas, W., Sowa, M. E., & Gygi, S. P. (2010) · Cell · doi:10.1016/j.cell.2010.12.001 · Cited by 1,778
Self-citationMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J., & Gygi, S. P. (2006) · Nature Biotechnology · doi:10.1038/nbt1240 · Cited by 1,577
Self-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationAnastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Quantitative flux analysis reveals folate-dependent NADPH production
Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114
Cited by
Items 201–300 of 345
Size-Specific Modulation of a Multienzyme Glucosome Assembly during the Cell Cycle
Jeon, M., Schmitt, D. L., Kyoung, M., & An, S. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.3c00037 · Cited by 13
Statin and Bisphosphonate Induce Starvation in Fast-Growing Cancer Cell Lines
Karlic, H., Haider, F., Thaler, R., Spitzer, S., Klaushofer, K., & Varga, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091982 · Cited by 17
“Recent data on the influence of cell cycle regulators (and their stimulation by oncogenes such as RAS) on metabolism [32,33] underline a close connection between energy metabolism and proliferation.”
Chaturvedi, N. K., Hatch, N. D., Sutton, G. L., Kling, M. J., Vose, J. M., & Joshi, S. S. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1520986 · Cited by 13
“Recent studies have also shown the cellular metabolic perturbation by both CDK4/CDK6 and HDAC inhibitors [32,33].”
BackgroundDOCK2 couples with LEF-1 to regulate B cell metabolism and memory response
Yang, L., Jing, Y., Wang, W., Ying, W., Li, L., Chang, J., Luo, L., Kang, D., Jiang, P., Liu, J., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.152 · Cited by 14
Cyclin D1 extensively reprograms metabolism to support biosynthetic pathways in hepatocytes
Wu, H., Kren, B. T., Lane, A. N., Cassel, T., Higashi, R. M., Fan, T. W. ‐., Scaria, G. S., Shekels, L. L., Klein, M. A., & Albrecht, J. H. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105407 · Cited by 14
“…cyclin D3 protein (in complex with Cdk6) phosphorylates and inhibits the activity of two key enzymes in the glycolytic pathway, PFK1 and pyruvate kinase M2, thereby inhibiting glycolysis and redirecting glucose metabolites into the PPP; importantly, cyclin D1/Cdk4 did not have this effect (36).”
BackgroundInfluentialInterplay of CDKs and cyclins with glycolytic regulatory enzymes PFK and PK
Lara‐Núñez, A., Guerrero-Molina, E. D., Vargas‐Cortez, T., & Vázquez-Ramos, J. M. (2024) · Journal of Plant Physiology · doi:10.1016/j.jplph.2024.154378 · Cited by 13
Cadmium inhibits apoptosis of human esophageal epithelial cells by upregulating CDK6
Yang, J., Guo, T., Xiao, L., Zhai, Y., Cheng, Y., Sun, H., Cui, Y., & Cheng, X. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.111146 · Cited by 12
Chong, Y. K., Tartey, S., Yoshikawa, Y., Imami, K., Li, S., Yoshinaga, M., Hirabayashi, A., Liu, G., Vandenbon, A., Hia, F., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abm5011 · Cited by 13
Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis
Rezaeian, A.-H., Inuzuka, H., & Wei, W. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.11.009 · Cited by 13
Schoos, A., Knab, V. M., Gabriel, C., Tripolt, S., Wagner, D. A., Bauder, B., Url, A., & Fux, D. A. (2019) · Veterinary and Comparative Oncology · doi:10.1111/vco.12514 · Cited by 14
Lu, J., Zhao, Z., & Ma, Y. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504020x15954139263808 · Cited by 12
Huang, W., & Wang, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-52 · Cited by 15
“Suppression of cyclin D3-CDK6 signaling resulted in tumor cell apoptosis (38).”
BackgroundSelf-citationNon‐Cell Cycle Functions of the CDK Network in Ciliogenesis: Recycling the Cell Cycle Oscillator
Krasińska, L., & Fisher, D. (2018) · BioEssays · doi:10.1002/bies.201800016 · Cited by 12
β-elemene promotes the senescence of glioma cells through regulating YAP-CDK6 signaling.
Yang, D., Xu, X., Wang, X., Feng, W., Shen, X., Zhang, J., Liu, H., Xie, C., Wu, Q., Miao, X., et al. (2021) · PubMed · Cited by 18
ZNF652 exerts a tumor suppressor role in lung cancer by transcriptionally downregulating cyclin D3
Xie, C., Zhou, X., Wu, J., Chen, W., Ren, D., Zhong, C., Meng, Z., Shi, Y., & Zhu, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07197-1 · Cited by 12
Emerging target discovery and drug repurposing opportunities in chordoma
Freed, D. M., Sommer, J., & Punturi, N. B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1009193 · Cited by 11
“CDK6 can upregulate glutathione and NADPH via phosphorylation of two glycolytic enzymes (122); depletion of these antioxidants can prime cells for ferroptosis (123).”
BackgroundMarinelli, O., Romagnoli, E., Maggi, F., Nabissi, M., Amantini, C., Morelli, M. B., Santoni, M., Battelli, N., & Santoni, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07619-1 · Cited by 13
Zhou, B., Qin, Y., Zhou, J., Ruan, J., Xiong, F., Dong, J., Huang, X., Yu, Z., & Gao, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16377 · Cited by 12
CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis
Shen, D., Yu, X., Fan, X., Liang, Y., Lu, D., Ke, Z., Wang, L., Xiang, P., & Xiao, J. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03325-7 · Cited by 10
“As a pivotal component of the cyclin D-CDK4/6-Rb signaling pathway, CDK6 directly phosphorylates PFKP at S679 and PKM2 at S37, thereby increasing pentose phosphate metabolism and serine metabolism in tumor cells, elevating intracellular NADPH levels, and promoting tumor cell growth [22].”
Targeting the cell-cycle machinery for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., Liu, J., & Wei, W. (2025) · Trends in Cell Biology · doi:10.1016/j.tcb.2025.08.008 · Cited by 12
Dysregulated Metabolism in Cancer
Isa, A. (2022) · Biomedical Research and Therapy · doi:10.15419/bmrat.v9i8.757 · Cited by 11
Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
Gao, X., Wu, Y., Chick, J. M., Abbott, A., Jiang, B., Wang, J., Comte‐Walters, S., Johnson, R. H., Oberholtzer, N. P., Nishimura, M. I., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112314 · Cited by 12
“30 Cells in the TME play important roles in regulating tumor progression.”
Self-citationWu, H., Wang, C., Liu, Y., Yang, C., Liang, X., Zhang, X., & Li, X. (2020) · Oncology Letters · doi:10.3892/ol.2020.12127 · Cited by 10
“It is well known that CCND3 is one of the highly conserved cyclin family members that serves a critical role in the cell cycle (19,20).”
BackgroundZhao, R., Feng, L., Zhu, Y., Yu, C., Zyuzin, M. V., Gai, S., Chen, D., Zhang, S., Zhu, H., & Yang, P. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202420600 · Cited by 15
Hu, Y., Weng, Y., Jiang, B., Li, X., Zhang, X., Zhao, B., Wu, Q. D., Liang, Z., Zhang, L., & Zhang, Y. (2019) · Science China Chemistry · doi:10.1007/s11426-018-9433-3 · Cited by 9
The Effect of CDK6 Expression on DNA Methylation and DNMT3B Regulation
Heller, G., Nebenfuehr, S., Bellutti, F., Ünal, H., Zojer, M., Scheiblecker, L., Sexl, V., & Kollmann, K. (2020) · iScience · doi:10.1016/j.isci.2020.101602 · Cited by 12
Broxmeyer, H. E. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151295 · Cited by 8
Kobayashi, H., Takase, S., Nishimura, H., Matsumoto, K., Harada, H., & Yoshida, M. (2023) · Cancer Science · doi:10.1111/cas.15713 · Cited by 8
CDK6 is essential for mesenchymal stem cell proliferation and adipocyte differentiation
Hu, A. J., Li, W., Pathak, A., Hu, G., Hou, X. S., Farmer, S. R., & Hu, M. G. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1146047 · Cited by 8
Yang, R., Liu, Y., Cheng, Y., Wang, C., Song, J., Lu, G., Feng, T., Wang, S., Sun, X., Meng, J., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.607910 · Cited by 8
“Moreover, multiple studies suggested that the JAK2/STAT3 signaling pathway was indispensable for myogenic differentiation by regulating the expression of MyoD and MEF (Wang et al., 2008).”
BackgroundPatra, A., Arora, A., Ghosh, S. S., & Saini, G. K. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00370 · Cited by 9
miR-708-5p Regulates Myoblast Proliferation and Differentiation
Xu, X., Lu, H. J., Xu, D. H., Yu, Z., Ai, N., Wang, K., Li, X., He, J., Jiang, J., Ma, H., et al. (2022) · Veterinary Sciences · doi:10.3390/vetsci9110641 · Cited by 7
“Cdk6 participates in cell cycle regulation; D-type cyclins together with Cdk6 and Cdk4 drive cell proliferation [33].”
BackgroundSchmitt, D. L., Dranchak, P. K., Parajuli, P., Blivis, D., Voss, T. C., Kohnhorst, C. L., Kyoung, M., Inglese, J., & An, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0289707 · Cited by 7
Zheng, M., Zhang, X., Chen, W., Xia, F., Yang, H., Yuan, K., & Yang, P. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0259 · Cited by 7
Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation
Atallah‐Yunes, S. A., Habermann, T. M., & Khurana, A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19425 · Cited by 7
Yu, T., Chen, D., Qi, H., Lin, L., & Tang, Y. (2024) · BioFactors · doi:10.1002/biof.2049 · Cited by 7
Recent Developments in Targeting the Cell Cycle in Melanoma
Hung, C., Nguyen, T. T. T., Poulikakos, P. I., & Polsky, D. (2025) · Cancers · doi:10.3390/cancers17081291 · Cited by 7
“These three cases had high Cyclin D3–CDK6 levels (in contrast to the levels detected in non-regressing tumors), and ribociclib treatment depleted NADPH and glutathione, resulting in increased ROS [63].”
Hosseinzadeh, E., Firoozpour, L., & Amanlou, M. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108514 · Cited by 7
Serendipitous Identification of a Covalent Activator of Liver Pyruvate Kinase
Battisti, U. M., Gao, C., Nilsson, O., Akladios, F. N., Lulla, A., Bogucka, A., Nain‐Perez, A., Håversen, L., Kim, W., Borén, J., et al. (2022) · ChemBioChem · doi:10.1002/cbic.202200339 · Cited by 9
Yang, C., Ikeda, K., Horie‐Inoue, K., Sato, W., Hasegawa, K., Takeda, S., Itakura, A., & Inoue, S. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.066 · Cited by 7
“Differential function of CDK6 not observed in CDK4 has been reported to efficiently phosphorylate pyruvate kinase M2 (PKM2) and phosphofructokinase (PFKP), thereby reducing the activity of these enzymes and leading to the metabolic reprogramming of glycolytic intermediates into the pentose phosphate pathway and serine…”
BackgroundZhao, J., Zhang, Z., Zuo, T., Yu, J., Yang, S., Yang, Y., Li, X., & Zheng, J. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112683 · Cited by 8
RUNX1 colludes with NOTCH1 to reprogram chromatin in T cell acute lymphoblastic leukemia
Islam, M. R., Jenkins, C. E., Cao, Q., Wong, J., Bilenky, M., Carles, A., Moksa, M., Weng, A. P., & Hirst, M. (2023) · iScience · doi:10.1016/j.isci.2023.106795 · Cited by 9
Safaroghli‐Azar, A., Mekonnen, L. B., Lenjisa, J. L., Milne, R. W., & Wang, S. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01794-7 · Cited by 5
“2E) [19].”
CDK6: an attractive therapeutic target for T-ALL/LBL
Li, W., Hu, J. K., & Hu, M. G. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2285775 · Cited by 5
“As a common effector of Notch 1 and AKT, CDK6 initiates and sustains cancer cells proliferation and survival [29,44,45] by providing them with energy and materials including ATP, antioxidants (GSH and NADPH), and carbon skeletons [71].”
BackgroundResultInfluentialMultiplexed Profiling of CDK Kinase Activities in Tumor Biopsies with Fluorescent Peptide Biosensors
Royet, C., Diot, S., Onofre, M., Lecki, L., Pastore, M., Reynès, C., Lorcy, F., Szablewski, V., Serre, I., & Morris, M. C. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00139 · Cited by 5
Role of miRNAs in Apoptosis Pathways of Immune Cells in Systemic Lupus Erythematosus
Azizan, A., Farhadi, E., Faezi, S. T., Jamshidi, A., Alikhani, M., & Mahmoudi, M. (2025) · Immunity Inflammation and Disease · doi:10.1002/iid3.70124 · Cited by 8
Yalaz, C., Bridges, E., Alham, N. K., Zois, C. E., Chen, J., Bensaad, K., Miar, A., Pires, E., Muschel, R. J., McCullagh, J., et al. (2022) · Cancer & Metabolism · doi:10.1186/s40170-023-00326-y · Cited by 6
“Metabolic pathways regulate cell cycle progression by contributing to biosynthesis [1–3] in a sustainable manner, limiting reactive oxygen species (ROS) exposure of newly synthesised DNA [4, 5], and providing the cell with ATP at critical points [6, 7].”
BackgroundImmuno-Oncology Integrative Networks: Elucidating the Influences of Osteosarcoma Phenotypes
Sharma, A., & Capobianco, E. (2017) · Cancer Informatics · doi:10.1177/1176935117721691 · Cited by 6
Wang, Y., Xu, N., Noah, M. L. N., Chen, L., & Zhan, X. (2025) · Metabolites · doi:10.3390/metabo15030203 · Cited by 5
“The investigation of T cell acute lymphoblastic leukemia (T-ALL) has discovered that phosphorylation of PKM2 by cyclin D3-CDK6 dependency hinders PKM2 enzyme activity and facilitates cancer cell proliferation through inhibition of tetramer formation [148].”
Chen, Z., Jingzhi, W., Chen, T., Zhang, Z., Xie, K., & Lin, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.144775 · Cited by 4
Dual targeting of CDK6 and LSD1 is synergistic and overcomes differentiation blockade in AML
Brault, L. M., Voisset, E., Desaunay, M., Boudet, A., Kousteridou, P., Letard, S., Carbuccia, N., Goubard, A., Castellano, R., Collette, Y., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00296-2 · Cited by 4
“Indeed, CDK6 is a component of several transcriptional complexes (Tigan et al, 2016); it also regulates DNA methyltrans-ferases (Heller et al, 2020) and core metabolic enzymes (Wang et al, 2017).”
Liu, R., Wang, X., Branigan, T. B., Griffin, D., McSweeney, C., Hao, J., Pantelidou, C., Herbert, Z. T., Jadhav, H., & Shapiro, G. I. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1406 · Cited by 6
Ju, N., Zhao, L., Yin, S., Yang, X., Zhou, J., Gao, J., & Qi, F. (2026) · International Journal of Cancer · doi:10.1002/ijc.70442 · Cited by 6
Lv, J.-L., Ren, Y.-S., Tan, Y., Chu, T., Cao, X.-Y., Liu, H.-Y., Ma, R., Zhang, H., Zheng, Q., Dong, G.-C., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155775 · Cited by 4
MAPK/ERK-PK(Ser11) pathway regulates divergent thermal metabolism of two congeneric oyster species
Wang, C., Du, M., Jiang, Z., Cong, R., Wang, W., Zhang, T., Chen, J., Zhang, G., & Li, L. (2024) · iScience · doi:10.1016/j.isci.2024.110321 · Cited by 9
LncRNA-ANRIL regulates CDKN2A to promote malignant proliferation of Kasumi-1 cells
Xu, J., Zhang, J., Zhang, C., Hu, H., Wang, S., Deng, F., Zhou, W., Liu, Y., Hu, C., Huang, H., et al. (2025) · Cell Division · doi:10.1186/s13008-025-00144-2 · Cited by 5
“For example, hyperactivated cyclin D3-CDK6 suppresses glycolysis by inhibiting PFK1 and PKM2 in acute lymphoblastic leukemia (T-ALL) cells, thereby promoting proliferation and drug resistance [33].”
Citrate oscillations during cell cycle are a targetable vulnerability in cancer cells
Icard, P., Alifano, M., & Simula, L. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189313 · Cited by 4
Zhao, J., Zha, Z.-A., Xie, W., Wang, H., Li, X., Sun, Q., & Sun, M. (2019) · PubMed Central · doi:10.7518/hxkq.2019.04.007 · Cited by 4
Self-citationAn HDAC9-associated immune-related signature predicts bladder cancer prognosis
Fu, Y., Sun, S., Bi, J., Kong, C., & Shi, D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0264527 · Cited by 4
Vargas‐Cortez, T., Guerrero-Molina, E. D., Axosco-Marín, J., Vázquez-Ramos, J. M., & Lara‐Núñez, A. (2023) · FEBS Letters · doi:10.1002/1873-3468.14704 · Cited by 4
Shi, Y., Du, J., Pan, W., Zhang, H., & Ba, Y. (2023) · journal of nutritional oncology · doi:10.1097/jn9.0000000000000008 · Cited by 6
Phosphofructokinase in glycolysis: Bridging enzymology and cell biology
Sharma, A., & An, S. (2026) · Experimental Cell Research · doi:10.1016/j.yexcr.2026.114887 · Cited by 5
Reduced cyclin D3 expression in erythroid cells protects against malaria
Marini, M. G., Mingoia, M., Steri, M., Tsamesidis, I., Idda, M. L., Manca, A., D’Avino, C., Virdis, F., Lodde, V., Mulas, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10110-9 · Cited by 5
“Given the reported effects of inhibition of cyclin D3 on oxidative stress in various cancer-cell lineages 3 , we hypothesized that rs112233623-T-mediated reduction of CCND3 expression might result in an increase in ROS in infected RBCs, and that this could eventually contribute to parasite…”
ATM promotes PFKP nuclear translocation to balance glycolysis and homologous recombination repair
Liu, H., Zhang, M., Xu, Z., Yang, Z., Pan, Y., Bai, Y., Zhao, X. T., Wang, W.-J., Yang, Y., & Wang, J. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag336 · Cited by 3
“During the G1 phase, CDK6 has been reported to phosphorylate PFKP and facilitate its transition from tetramers to dimers, thereby promoting its trafficking to the nucleus [ 48 , 61 ].”
Cancer Drug Resistance and Metabolic Reprogramming
Jan, S., Fatima, K., Wani, A., Malik, F. A., & Khan, S. U. (2024) · Springer eBooks · doi:10.1007/978-981-97-1666-1_6 · Cited by 3
Huang, P., Chen, C., Lin, Y., Lin, H., & Fang, S. (2024) · Plant Cell & Environment · doi:10.1111/pce.15113 · Cited by 3
Su, Y., Ma, Y., Wang, Y., Xu, P., Guo, M., Cao, H., Xin, J., Wu, X., Liu, X., Chen, S., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.100921 · Cited by 6
“Previous studies have suggested that CCND3 accelerates cell cycle progression across various tumors [21-23].”
The differential regulation of the urea cycle in tumors goes awry
Abou‐Shanab, A. M., Khedr, M. A., & Matosevic, S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117365 · Cited by 5
Cellular signals integrate cell cycle and metabolic control in cancer
Akekawatchai, C., & Jitrapakdee, S. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.01.002 · Cited by 4
Zhao, X., He, X., Wang, M., Zhang, H., Cheng, J., & Wang, H. (2022) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2022044134 · Cited by 3
Self-citationDrivers of de novo Serine/Glycine synthesis in acute leukemia
Verstraete, P., Keersmaecker, K. D., & Kampen, K. R. (2023) · FEBS Letters · doi:10.1002/1873-3468.14700 · Cited by 3
Martín, R., Gaitán, N., Jarlier, F., Feuerbach, L., de Soyres, H., Arbonés, M., Gutman, T., Puiggròs, M., Ferriz, A., Gonzalez, A., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100639 · Cited by 4
“50,52 Lastly, other genes, used as support for the diagnosis of different cancer types, such as FOXP1 and NOTCH2 , also presented mutations that were discordantly detected between the three pipelines.”
Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer
(2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0200 · Cited by 3
Gu, S., Niu, X., Mao, F., & Xu, Z. (2018) · RSC Advances · doi:10.1039/c8ra08083f · Cited by 3
RetractedImmunometabolism and potential targets in severe COVID-19 peripheral immune responses
Wang, S., Zeng, X. L., Wang, Y., Chen, Y., Wang, C., Dongzhi, Z., Zhang, F., & Zhao, Y. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.07.001 · Cited by 3
Starving multiple myeloma cells via CDK7 inhibition
Sacco, A., & Roccaro, A. M. (2023) · Blood · doi:10.1182/blood.2023020254 · Cited by 3
Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
Zhang, S., Zhang, R., Xia, Y., & Cao, D. (2025) · PLoS ONE · doi:10.1371/journal.pone.0336767 · Cited by 3
Discovery of WWZ-11-098: a rigid and selective CDK6 degrader
Zhang, W., Wen, J., Wu, Y., Xuan, Y., Han, Q., Chen, X., Yu, J., Yu, H., & Jiang, B. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118569 · Cited by 2
Ma, C., Ji, X., Huang, W., Guo, S., Wang, L., Wu, X., Zheng, H., & Wang, J. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00005 · Cited by 2
Genetic variant within CDK6 regulates immune response to palbociclib treatment
Serra, V., Orrù, V., Steri, M., Fiorillo, E., Cucca, F., & Żołędziewska, M. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108777 · Cited by 2
Bruceantinol works as a CDK2/4/6 inhibitor to inhibit the growth of breast cancer cells
Sun, L., Wang, Y., Li, J., Xu, S., Xu, S., & Li, J. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110999 · Cited by 3
Yoshimori, T., Kawami, M., Kumagai, Y., Futatsugi, S., Yumoto, R., Uchida, Y., & Takano, M. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106601 · Cited by 2
Lara‐Núñez, A., Garza‐Aguilar, S. M., Páez-Franco, J. C., Galindo‐de‐la‐Rosa, J., & Vallejo‐Becerra, V. (2025) · Physiologia Plantarum · doi:10.1111/ppl.70119 · Cited by 2
Prognostic significance of CDK6 amplification in esophageal squamous cell carcinoma
Liu, K., Lu, H., Jiang, D., Guan, Y., Xu, H., Sun, Q., Jiang, Q., Zheng, J., Chen, H., Zhang, F., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100698 · Cited by 2
Sarkar, P., Misra, S., Ghosal, A., Mukherjee, S., Ghosh, A., & Sundaram, G. (2023) · Biology Open · doi:10.1242/bio.060145 · Cited by 2
“…6-bisphosphatase3 (PFKFB3), hexokinase 2 (HK2), phosphofructokinase, platelet type (PFKP) and pyruvate kinase M2 (PKM2) have been reported to be regulated in a cell cycle-dependent manner (Jennifer et al., 2007; Herrero-Mendez, 2009; Almeida et al., 2010; Sakamaki et al., 2006; Wang, 2017).”
BackgroundRNA-binding protein NOVA1 promotes acute T-lymphocyte leukemia progression by stabilizing USP44 mRNA
Zhang, B., Sun, R., Gu, M., Jiang, Z., Wang, Y., Zhang, L., Liu, X., & Chi, Z. (2023) · Biochemistry and Cell Biology · doi:10.1139/bcb-2023-0092 · Cited by 1
Cui, Z., Yang, Y., Wang, C., Zhu, J., Jiao, H., Wang, L., Zhang, S., He, H., & Zhong, H. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob00501a · Cited by 1
Unveiling oncogene-induced senescence: a new frontier in prostate cancer prognosis and therapy
Peng, Y., Qiu, X., Cai, J., Li, Y., & Wei, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-03893-2 · Cited by 3
Eprenetapopt in combination with Palbociclib exerts synthetic lethality in mantle cell lymphoma
Dong, L., Zhang, Y., Chen, F., Jiang, W., Qian, S., Song, W., Yang, S., Wu, X., Li, Z., & Zhang, M. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102794 · Cited by 1
“Additional studies have reported that Palbociclib modulates the cellular GSH/NADPH redox system, leading to increased intracellular ROS levels and the induction of apoptosis [24].”
Wu, Z., Zheng, S., Li, M., Zhang, X., Zheng, W., Wang, P., Gong, Q., Wu, X., Wu, J., Liang, Y., et al. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf184 · Cited by 1
Luca, E., Shapiro, I., Debaix, H., Zitzmann, K., Wang, K., Auernhammer, C. J., Beuschlein, F., Nölting, S., & Hantel, C. (2026) · Biology Open · doi:10.1242/bio.062358 · Cited by 1
Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancer
Telang, S., Clem, B. F., Miret, A. A. H., Price, L., Dougherty, S. M., Schmitz, A., Yin, X., Ma, X., Zhang, X., Chesney, J., et al. (2026) · Breast Cancer Research · doi:10.1186/s13058-026-02336-2 · Cited by 1
“Emerging evidence indicates that CDK4/6 signaling intersects with metabolic regulation through both RB-dependent transcriptional programs and direct effects on metabolic enzymes; however, how these changes reshape glucose utilization in tumors has not been fully elucidated [14, 31, 32].”
Parreiras, S., & Serpa, J. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_15 · Cited by 1
Yu, J. X., Zhang, W., Ma, Q., & Gao, Y. (2022) · Science of Advanced Materials · doi:10.1166/sam.2022.4252 · Cited by 1
Yang, J., Wang, L., Sun, H., Zhao, Z., Ma, Y., Hu, Z. J., Zhai, L., & Wang, Y. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.031 · Cited by 1
Song, J., Yu, Y., Yan, Z., Xiao, S., Zhao, X., Wang, F., Fang, Q., & Yè, G. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1217954 · Cited by 1
“Caspase 3/7 activation was measured using a Caspase-Glo® 3/ 7 Assay (Promega; Madison, WI, United States) according to the manufacturer’s protocol (Wang et al., 2017).”
MethodCDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma
Zhu, S., Yang, H., Liu, L., Jiang, Z., Ji, J., Wang, X., Zhong, L., Liu, F., Gao, X., Wang, H., et al. (2023) · Journal of Bioinformatics and Systems Biology · doi:10.26502/jbsb.5107060 · Cited by 1
“For example, CDK6 has unique roles in cell development [34], DNA protection [35], metabolic homeostasis [36], centrosome stability [37] as well as in cancer cell survival [38], infiltration [39], immune evasion [40], and T-cell activation [41].”
BackgroundSelf-citationTCF3 :: ZNF384 induces steroid resistance in B‐cell precursor acute lymphoblastic leukemia cells
Kusano, S., Ueno‐Yokohata, H., Hori, M., Ishibashi, T., Fujimura, J., Shimizu, T., Ohki, K., & Kiyokawa, N. (2025) · Pediatrics International · doi:10.1111/ped.70078 · Cited by 1
“33 In addition, Bellutti et al. showed that CDK6 acts as a pro-survival factor for preleukemic cells and is required to antagonize oncogene-induced activation of tumor protein 53 (TP53).”
Duso, B. A., Ferraro, E., Mazzarella, L., Jeremias, C. D., & Curigliano, G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1604136 · Cited by 1
“The inhibition of this pro-survival oncoprotein with palbociclib showed to deplete NADPH and glutathione, increasing the levels of reactive oxygen species and consequently sending tumors cells into apoptosis [49].”
BackgroundAwasthi, P., Srivastava, A. K., Yadav, V., Singh, R., Yadav, S., Kidiyoor, G. R., & Kumar, A. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00060-7 · Cited by 1
Metadata
- Authors
- Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., Keibler, M. A., Sicinska, E., Gerdemann, U., Haining, W. N., Roberts, T. M., Polyak, K., Gygi, S. P., Dyson, N. J., & Sicinski, P.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Massachusetts Institute of Technology (US)
- Dana-Farber Cancer Institute (US)
- Broad Institute (US)
- ORCID
- Venue
- Nature
- Published
- 2017-06
- Volume
- 546
- Issue
- 7658
- Pages
- 426-430
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5516959
- OpenAlex
- W2624626767
- Cited by
- 347
- References
- 37
- Citations by year
- 2026: 20 · 2025: 31 · 2024: 29 · 2023: 43 · 2022: 41 · 2021: 45 · 2020: 61 · 2019: 32 · 2018: 30 · 2017: 15
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- The Novartis Repository (Novartis) (submittedVersion)
- Funders
- National Cancer Institute (R01CA190509, P50CA090381, F32CA165856, T32CA009361, R01CA202634, P01CA080111, R01CA163698, R01CA083688)
- National Institute of General Medical Sciences (R01GM067945)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin D3, CDK6, cyclin-dependent kinases, tumor cell survival, glycolysis, 6-phosphofructokinase, PKM2, pentose phosphate pathway, serine pathway, NADPH, glutathione, reactive oxygen species, oxidative stress, apoptosis, CDK4/6 inhibitors, RB1, patient selection
- MeSH terms
- Aminopyridines, Animals, Cell Cycle, Cell Survival, Female, Glycolysis, Humans, Neoplasms, Pentose Phosphate Pathway, Phosphofructokinase-1, Phosphorylation, Purines, Pyruvate Kinase, Serine, Apoptosis, Reactive Oxygen Species, Oxidative Stress, Xenograft Model Antitumor Assays, Reactive Nitrogen Species, Cell Line, Tumor, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Cyclin D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.